Publications
2023
Aloys Hüttermann/Ferdinand Weber
Patentrechtssystem/e in Europa
NJW 2023, 950
Aloys Hüttermann
Lieben Sie Brahms? Oder: Die drei Antagonismen im gewerblichen Rechtsschutz
Mitt. 2023, 58
Aloys Hüttermann
The new UPC system (in Japanese language)
AIPPI Journal Vol. 68 NO. 2, p. 1, 2023
2022
Ulrich Storz
The COVID-19 vaccine patent race
Nature Biotechnology 40, 1001–1004 (2022)
https://doi.org/10.1038/s41587-022-01376-1
Aloys Hüttermann
Can Clarity of an Amended Patent Claim Be Challenged Before the UPC (?)
GRUR International 2022, 633–635
Wasilis Koukounis
Die eigenen Marken und Patente in Russland schützen
VDI nachrichten digital, 4. Mai 2022
Wasilis Koukounis
Diese Faktoren entscheiden über den Wert eines Patents
VDI nachrichten digital, 30. März 2022
Wasilis Koukounis
Patents for professionals – What risks of patent infringement lurk in the Internet of Things
VDI nachrichten digital, 23. Februar 2022
Wasilis Koukounis
Patents for professionals – The deserved protection for the digital twin
VDI nachrichten digital, 26. Januar 2022
Dirk Schulz
Interpretation of patent claims according to German and European practice
IPRB 2022, 20-24
2021
Wasilis Koukounis
Patents in practice – the fight against plagiarism
VDI nachrichten, 17. Dezember 2021, Nr. 50/51/52
Aloys Hüttermann
The decision G 1/21: Everything must change so that everything remains as it is (?)
Mitt. Dt. Patentanw. 2021, 526
Wasilis Koukounis
Patents in practice – The smart fight against copying
VDI nachrichten, 19. November 2021, Nr. 46
Wasilis Koukounis
Patents in practice – Responding correctly to a lawsuit
VDI nachrichten, 15. Oktober 2021, Nr. 41
Aloys Hüttermann
The new German patent law
AIPPI Journal 2021, Vol. 66, No. 9, S. 28
Wasilis Koukounis
Patents in practice – What goes around comes around
VDI nachrichten, 17. September 2021, Nr. 37
Wasilis Koukounis
Patents in practice – There can only be one
VDI nachrichten, 20. August 2021, Nr. 33/34
Wasilis Koukounis
Patents in practice – money instead of injunction
VDI nachrichten, 6. August 2021, Nr. 31/32
Ulrich Storz
The patent maze of COVID 19 vaccines.
Expert Opin Ther Pat. 2021 Jun 17.
doi: 10.1080/13543776.2021.1945581.
Epub ahead of print. PMID: 34139951.
Wasilis Koukounis
Patents in Practice – Multiple Paths to Protection
VDI nachrichten, 18. Juni 2021, Nr. 24
Wasilis Koukounis
Patents in practice – suspend patents that do not yet exist?
VDI nachrichten, 21. Mai 2021, Nr. 20
Wasilis Koukounis
Patents in practice – learning from Lego
VDI nachrichten, 23. April 2021, Nr. 16
Wasilis Koukounis
Patents in practice – search protects against lawsuit
VDI nachrichten, 19. März 2021, Nr. 11
Wasilis Koukounis
Patents in Practice – The Pitfalls of Enlargement
VDI nachrichten, 19. Februar 2021, Nr. 7
Aloys Hüttermann
The possible significance of recent ECJ decisions for the unitary patent system
Mitt. dt. Patentanw. 2021, 4
Wasilis Koukounis
Patents in practice – One patent for all of Europe
VDI nachrichten, 15. Januar 2021, Nr. 1/2/3
2020
Wasilis Koukounis
Patents in practice – too much secrecy can do harm
VDI nachrichten, 20. November 2020, Nr. 47
Wasilis Koukounis
Patents in practice – Inventive or not?
VDI nachrichten, 16. Oktober 2020, Nr. 42
Wasilis Koukounis
Patents in practice – When is “new” not new after all?
VDI nachrichten, 18. September 2020, Nr. 38
Wasilis Koukounis
Patents in practice – Square, practical, legally secure
VDI nachrichten, 4. September 2020, Nr. 36
Wasilis Koukounis
Protection for digital inventions
MEO : das Wirtschaftsmagazin der IHK für Mülheim an der Ruhr, Essen, Oberhausen, 3/2020
Wasilis Koukounis
Patents in practice – Asia more active
VDI nachrichten, 26. Juni 2020, Nr. 33
Ulrich Storz
The nine lives of epitope-based antibody patent
Hum Antibodies. 2020; 28(2):89-110. doi: 10.3233/HAB-190395.
Aloys Hüttermann
Sisvel ./. Haier, the first FRAND decision of the Federal Court of Justice
IPR Daily
Aloys Hüttermann
The decision G 3/19 or the art of authority-preserving conflict resolution (?)
Mitt. dt. Patentanw. 2020, 255
Wasilis Koukounis
Patents in practice – First nationally, then worldwide
VDI nachrichten, 29. Mai 2020, Nr. 22/23
Wasilis Koukounis
Patents in practice – protective rights for every need
VDI nachrichten, 1. Mai 2020, Nr. 18/19
Dr. Aloys Hüttermann
The draft for a new German patent law (in Japanisch)
AIPPI Journal Vol. 65 NO. 4, p. 40, 2020
Wasilis Koukounis
Patents in practice – unitary patent on hold
VDI nachrichten, 27. März 2020, Nr. 13
Wasilis Koukounis
Patents in Practice – Getting a Trademark in Bad Faith
VDI nachrichten, 21. Februar 2020, Nr. 8
2019
Dr. Sonja Althausen, Dr. Aloys Hüttermann
Chapter on trademark and patent law in Götting/Meyer/Vormbrock (eds.).
Intellectual property and competition law,
Nomos, 2. Auflage 2019
Wasilis Koukounis
Patents in practice – When does the right of prior use protect?
VDI nachrichten, 6. Dezember 2019, Nr. 49/50
Wasilis Koukounis
Patents in practice – When employees invent
VDI nachrichten, 8. November 2019, Nr. 45
Wasilis Koukounis
Patents in practice – The right way to deal with trolls
VDI nachrichten, 4. Oktober 2019, Nr. 40
Dr. Aloys Hüttermann
Does the UPC allow for confidentiality orders in FRAND proceedings?
GRUR Int. 2019, 1148
Wasilis Koukounis
Patents in practice – patent waivers can be expensive
VDI nachrichten, 20. September 2019, Nr. 38
Wasilis Koukounis
Patents in practice – How software can be protected
VDI nachrichten, 9. August 2019, Nr. 32/33
Aloys Hüttermann
Who decides if there is a conflict between Implementing Regulations and Articles of the EPC?
GRUR Int. 2019, 896
Aloys Hüttermann
Repealing the “sliding” non-use defense – the right way to go?
Mitt. dt. Patentanw. 2019, 62
Wasilis Koukounis
Patents in practice – the underestimated utility model
VDI nachrichten, 12. Juli 2019, Nr. 28
Dirk Schulz
Divisional Practice Around the Globe (Europe)
Special Feature by AIPF Patent Committee, 19. Juni, 2019
Wasilis Koukounis
Praise and reward for innovations – on the obligation to report inventions
VDI nachrichten, 7. Juni 2019, Nr. 23
2018
Aloys Hüttermann
The assessment of disclosure in the EPO’s decision-making practice – conclusions from decisions G1/15 and G1/16
Sammelband zu den Düsseldorfer Patentrechtstagen 2018, 22
Ulrich Storz
Ethics and Biotech patents – where two worlds collide.
In: Müller/Rosenau (ed): Stammzellen – iPS-Zellen – Genomeditierung. Schriften zum Bio-, Gesundheits- und Medizinrecht, Band 34, Nomos-Verlag 2018
Ulrich Storz
CRISPR Cas9 – Licensing What Can’t Be Licensed
Les Nouvelles (2018), 123 – 131
Aloys Hüttermann
Comments on BGH IZR 164/16- Perfume trademarks
Mitt. dt. Patentanw. 2018, 141
Torsten Exner
EPÜ Art. 56, 112 – Cyclic Protein Kinase Inhibitors (Evidence of the existing effect),
Mitt. dt. Patentanw. 2018, 71
Aloys Hüttermann
Farewell to Hilbert (?) – The decisions G1/15 and G1/16
Mitt. dt. Patentanw. 2018, 53
Torsten Exner/Aloys Hüttermann
Is the EPO using “plausibility” to introduce invention ownership as a patenting criterion?
GRUR Int 2018, 97
2017
Ulrich Storz
CRISPR cas9 − licensing the unlicensable
Journal of Biotechnology
Available online 14 November 2017, https://doi.org/10.1016/j.jbiotec.2017.11.005
X. Deng, U. Storz, B. Doranz B
Enhancing antibody patent protection using epitope mapping information, mabs
Available online 09 November 2017, http://dx.doi.org/10.1080/19420862.2017.1402998
Ulrich Storz
Of patents and patent disputes – the TNFα patent files. Part 2 – Enbrel, Remicade, Cimzia and Simponi.
Accepted in Human Antibodies, 2017
Aloys Hüttermann
The qualified reference in nullity proceedings – decisive for the admission of late submissions
Mitt. dt. Patentanw. 2017, 193
Torsten Exner/Aloys Hüttermann/Stefan Michalski
Patent grant as a Hilbert program – possibilities and limits of the EPO’s rule-based examination practice
Mitt. dt. Patentanw. 2017, 104
Aloys Hüttermann/Ulrich Storz
Estoppel even when functional patent claims fail? Remarks
to BGH „Pemetrexed“
Mitt. dt. Patentanw. 2017, 49
2016
Aloys Hüttermann
Unitary Patent and Unified Patent Court
Verlag Carl Heymanns, Köln, 1. Auflage, 2016
Ulrich Storz & Timo Faltus
Patent eligibility of stem cells in Europe: where do we stand after 8 years of case law?
Regenerative Medicine, January 2017,Vol. 12, No. 1, Pages 37-51 , DOI 10.2217/rme-2016-0099
Gresl T., Storz U., Sandercock C.
An update on obtaining and enforcing therapeutic antibody patent claims
Nature Biotech. 34(12), 1242–1244 (2016)
Storz U.
Of patents and patent disputes – the TNFα patent files. Part 1
Humira. Human Antibodies. 2016 Oct 21
Aloys Hüttermann
What does the Brexit vote mean for IP in Europe?
Mitt. dt. Patentanw. 2016, 353
Aloys Hüttermann
Patents — Paper Tigers or Real Tigers
Mitt. dt. Patentanw. 2016, 101
Aloys Hüttermann
Do the procedural rules of the Unified Patent Court lead to a renaissance of former (outdated) practices?
Mitt. dt. Patentanw. 2016, 5, S. 212 ff.
Ulrich Storz
Extending the market exclusivity of therapeutic antibodies through dosage patents
mAbs 2016, doi: 10.1080/19420862.2016.1180491
Kevin R. Greenleaf, Michael W. O’Neill, Aloys Hüttermann
Understanding the Unified Patent Court: The Next Rocket-Docket for Patent Owners?
ABA Landslide Magazine 2016, 44
Aloys Hüttermann
Patents – paper tigers or real tigers?
Mitt. dt. Patentanw. 2016, 3, S. 101 ff.
Aloys Hüttermann
Current developments in the field of the unitary patent/unitary patent court
VPP Rundbrief Nr. 1 März 2016, S. 1 ff.
2015
Aloys Hüttermann
The ECJ and the Unified Patent Court – Lessons from the Spain Judgments C-146/13 and C-147/13?
Mitt. dt. Patentanw. 2015, 11, S. 498 ff.
Ulrich Storz
Intellectual property issues of immune checkpoint inhibitors. mAbs 2015
mAbs 2015, doi: 10.1080/19420862.2015.1107688
Ulrich Storz
Antibody-drug conjugates: Intellectual property considerations. mAbs 2015, doi: 10.1080/19420862.2015.1082019
I. de Baere, Ulrich Storz
Strawman oppositions – Advantages and Disadvantages. Epi information 3/2015, 109
Aloys Hüttermann
The EU system of geographical indications — an Overview
Chung-Ang University, Culture, Media, and Entertainment Law, Vol.9 No.1, p. 141-170
Aloys Hüttermann
On the commonality between literature and patents
IPO Law Journal, 27.03.2015
Aloys Hüttermann
Dual jurisdiction for claims based on lack of entitlement in the upcoming unitary patent system
Mitt. dt. Patentanw. 2015, 3, S. 100 f.
Aloys Hüttermann, Klaus Kupka
On the Role of the European Court of Justice in the Future Unitary Patent System
Mitt 2015, 1, 6-10
2014
Aloys Hüttermann
Art. 32, 1 i) of the Agreement on a Unified Patent Court – a revolution in the European patent system (?) Mitt 2014, 12, 546-547
Aloys Hüttermann
Unconventional Trademarks in Germany and the EU — an Overview Chung-Ang University, Culture, Media, and Entertainment Law, Vol.8 No.2, p. 133-160
Ulrich Storz
Rituximab: How approval history is reflected by a corresponding patent filing strategy.
mAbs 2014; 6:820 – 837
Aloys Hüttermann, Ralf Malessa, Jan Sommer
Art. 112a EPC – a first stocktaking,
GRUR. 2014, 5, 448-451
Aloys Hüttermann
Are some patent owners more equal than others (?) – Older rights in the upcoming unitary patent system
Mitt. dt. Patentanw. 2014, 2, S. 72-73
Andreas Hübel
Anticipation of Pharmaceutical Product Claims by Clinical Studies: A European Perspective
Chemical Practice Chronicles, Volume 2, Issue 1, pages 9 – 12, Winter 2014
Aloys Hüttermann
Unitary Patent and Unified Patent Court Chung-Ang University,
Culture, Media, and Entertainment Law, Vol.7 No.2, p. 147-185
2013
Aloys Hüttermann
Recent Rule Changes to the European Patent Convention
The IPO Intl’ Committee Newsletter, December 2013, p. 8-9
Aloys Hüttermann
Considerations on equivalent patent infringement
Mitt. dt. Patentanw. 2013, 11, S. 490-493
Ulrich Storz
Patentability Requirements of Biotech Patents In: Storz (ed), SpringerBriefs in Biotech Patents: Biopatent Law: European vs. US Patent Law , 2014, 1-21. DOI: 10.1007/978-3-642-41293-6_1
Aloys Hüttermann
Appeal from the living dead (?): The case G1/13 before the EPO’s great board of appeal
The IPO Intl’ Committee Newsletter, September 2013, p. 8-9
Aloys Hüttermann
Damn the Torpedoes — ECJ Allows Negative Declaratory Judgements
The IPO Intl’ Committee Newsletter, May 2013, p. 9-10
Aloys Hüttermann
Two theses about patents
Mitt. dt. Patentanw. 2013, 4, S. 181-187
Timo Faltus, Ulrich Storz
The Unpatentability of Human Embryonic Stem Cell Inventions within the European Union and under the European Patent Convention
Poster beim 7. Internationalen Meeting des Kompetenznetzwerks Stammzellforschung NRW, 23. – 24. April 2013, Köln
Aloys Hüttermann
On the commonality of literature and patents
Mitt. dt. Patentanw. 2013, 3, S. 113-121
2012
Andreas Huebel
The Limits of Patentability: Plant Biosciences
In: Storz (ed), SpringerBriefs in Biotech Patents: Limits of Patentability,
2012, 1-8. DOI: 10.1007/978-3-642-32841-1_1
Ulrich Storz
The Limits of Patentability: Stem Cells
In: Storz (ed), SpringerBriefs in Biotech Patents: Limits of Patentability,
2012, 9-32. DOI: 10.1007/978-3-642-32841-1_2
Aloys Hüttermann
The Limits of Patentability: Genes and Nucleic Acids
In: Storz (ed), SpringerBriefs in Biotech Patents: Limits of Patentability,
2012, 33-44. DOI: 10.1007/978-3-642-32841-1_3
Colin G Sandercock, Ulrich Storz
Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope
Nature Biotechnology 30, 615–618 (2012)
Ulrich Storz
Protecting Biotech Inventions.
NRW Spotlight on Biotechnology (3), 2012, 13 – 1
Ulrich Storz
IP Issues of Therapeutic Antibodies
In: Storz (ed), SpringerBriefs in Biotech Patents: Intellectual Property Issues: Therapeutics, Vaccines and Molecular Diagnostics,
2012, 1-16. DOI: 10.1007/978-3-642-29526-3_1
Ulrich Storz
The Cabilly patents: Status quo and relevance for antibody companies
mAbs 4 (2), 2012, 274
Aloys Hüttermann
Coming-up amendments to German IP Law
The IPO Committee Newsletter, April 2012, p. 5-6
Andreas Huebel
General Issues of Biotech Patents.
In: Storz (ed), SpringerBriefs in Biotech Patents: Biopatent Law: Patent Strategies and Patent Management,
2012, 1-12.. DOI: 10.1007/978-3-642-24846-7_1
Ulrich Storz
Patent Lifecycle Management, Supplementary Protection Certificates and Data Exclusivity in Biopharmaceutics.
In: Storz (ed), SpringerBriefs in Biotech Patents: Biopatent Law: Patent Strategies and Patent Management,
2012, 25-41. DOI: 10.1007/978-3-642-24846-7_3
2011
Sonja Althausen, Nicole Griebel, Aloys Hüttermann
in: Götting / Meyer / Vormbrock (Hrsg.) Gewerblicher Rechtsschutz und Wettbewerbsrecht, Praxishandbuch, Nomos Verlag, Baden-Baden, 2011
Author of several chapters in the field of trademark law (Althausen, Griebel) and patent law (Hüttermann), respectively.
Andreas Huebel
Patentability of pluripotent stem cells unlikely although they are not considered as embryoMitt. dt. Patentanw. 2011, 11, S. 494
Ulrich Storz
International intellectual property strategies for therapeutic antibodies
mAbs 3 (6), 2011, 596
Ulrich Storz
Innovation Protection in the Pharmaceutical Industry, Part 4: Supplementary Protection for Pharmaceutical Products
Pharmind 7/2011, 1272
Claudia Meinken
Innovation Protection in the Pharmaceutical Industry, Part 3: Patent Life Cycle Management Strategies
Pharmind 6/2011, 1058
Andreas Hübel
Protection of Innovation in the Pharmaceutical Industry, Part 2: Patent Granting Procedures and International Filing Strategies
Pharmind 5/2011, 868
Ulrich Storz
Intellectual property protection: Strategies for antibody inventions
mAbs 3 (3), 2011, 310
Andreas Hübel
Essentials on Essentially Biological Processes for the Production of Plants: Decisions G2/07 (Broccoli case) and G1/08 (Tomato case) of the Enlarged Board of Appeal of EPO
European Intellectual Property Review, Vol. 33 (5), 328-330 (2011)
Aloys Hüttermann
Innovation Protection in the Pharmaceutical Industry, Part 1: What is protectable in the pharmaceutical industry?
pharmind 4/2011, 714
Hüttermann A., Storz U.
The potential impact of the ECJ’s Monsanto ruling on the concept of substance protection for chemical compounds.
Mitt. dt. Patentanw. 2011, 1, S. 1–4.
2010
Aloys Hüttermann
The Monsanto Case — A first landmark ruling of the ECJ
The IPO Committee Newsletter, December 2010, p. 6-10
Ulrich Storz, Johanna Driehaus
The problem of patenting human Stem Cells,
Zeitschrift Regenerative Medizin 2010 (2), 70 – 73
Aloys Hüttermann
The new Rule 62(a) of the European Patent Convention,
The Federal Circuit Bar Newsletter, Vol. XV, Nr. 11 — October 2010
Hüttermann A., Storz U.
Monsanto Soy Bean Patent Cases — A Paradigm Shift Gathering In Case The ECJ Takes Over Patent Jurisdiction,
les Nouvelles Sept 2010, 156 – 159
Aloys Hüttermann, Ulrich Storz
Thinking is not acting – On the decisions G 1/07 and G 1/04
Mitt. dt. Patentanw. 2010, 05/10, S. 213-214
Ulrich Storz
Rule 164 EPC and the problem of inconsistency a posteriori,
epi information 1/10, 24 – 27
R. Kontermann and S. Dübel
Antibody Engineering Vol. 2, Springer-Verlag Berlin, 2010.
Kapitel IP Issues in the Therapeutic Antibody Industry von U. Storz
2009
Ulrich Storz
Recent changes in the European Patent System.
Lexis Nexis Emerging Issues Analysis,
2009 Emerging Issues 4257
Hüttermann A., Storz U.
Comparison between Biotech- and Software-related Patents.
European Intellectual Property Review 12, 2009
Driehaus J., Hüttermann A., Storz U.
Humane Embryonale Stammzellen in Deutschland und Europa:
An overview of generation, use and patenting.
Bioethica Forum, issue 1, 2009, S. 37 – 42
2008
Hüttermann A., Storz U.
On the patentability of smart breeding processes.
Mitt. dt. Patentanw. 06/2009, 277 2008
Hüttermann, A.
Why (still) patents?
Chemie & Wirtschaft(E-Journal der Fachgruppe Vereinigung für Chemie und Wirtschaft der Gesellschaft Deutscher Chemiker), 1/2008, 36
Storz U, Wind-Falk J.
The reinstatement of the priority period and the resulting problems
epi-Information 2/2008, 68 – 70
Bräse, Stefan / Bülle, Jan / Hüttermann, Aloys
Organic and bioorganic chemistry
The basic knowledge for master and diploma exams 1. Auflage (Continuation of the book: The basic knowledge of organic chemistry at Thieme, 2000)Wiley-VCH, Weinheim
Michalski S., Hüttermann A.,
Country Chapter: Germany World Trademark Yearbook 2008
Hüttermann A., Storz U.
Recent changes in the field of utility model law.
GRUR 2008 Heft 3, 230
2007
Hüttermann A., Storz U., Tellmann C.
On the question of a defect of title pursuant to Section 435 of the German Civil Code (Bürgerliches Gesetzbuch – BGB) in the case of items marked with a trademark if the trademark had not yet been registered at the time of the sale.
Mitt. dt. Patentanw. 2007, 389
Michalski S., Hüttermann A,
Country Chapter: Germany World Trademark Yearbook 2007
2006
Hüttermann A., Storz U.
The concept of ‘identity’ according to § 15, para. 1, Nr. 2 GbmG.
Mitt. dt. Patentanw. 2006, 343
Hüttermann A., Storz U.
The impact of decisions G 2/04 and G 3/04 in the practice of opposition.
Mitt. dt. Patentanw. 2006, 410
Hüttermann A., Storz U.
The effects of the changes in the implementation of the Biopatent Directive in Germany.
Kursbuch Biopolitik Vol. 3 Berlin 2006
Michalski S., Hüttermann A,
Country Chapter: Germany World Trademark Yearbook 2006
Hüttermann A., Storz U.
The BGH decision ‘Demonstration cabinet’ – a revolution in industrial property protection?
Neue Juristische Wochenschrift 2006
2005
Hüttermann A., Storz U.
On the graphic representability of sound marks according to the recent case law of the European Court of Justice.
Mitt. dt. Patentanw. 2005, 156
Michalski S., Hüttermann A.
Country Chapter: Germany World Trademark Yearbook 2006
Hüttermann A.
How to get that 3D shape mark registered.
Managing IP 2005, April suppl. Brand Management Focus 2005
Hüttermann A., Storz U.
On the effects of the amendments to the Patent Act due to the implementation of the Biopatent Directive.
Zeitschr. f. Biopolitik 2005, 45